FDA approves triple melasma combination

Clinicians discuss how type 2 inflammation informs treatment decisions across AD, prurigo nodularis, CSU, and bullous pemphigoid.

A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.

At a Dermatology Times Case-Based Roundtable, Vishal A. Patel, MD, led a discussion on treatment selection, tolerability, and individualized care for patients with advanced basal cell carcinoma.

Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.

October brought FDA approvals in urticaria and HSV, new regulatory filings, and phase 3 advances in HS, psoriasis, and rare diseases.

Gaurav Singh, MD, explores how gene expression profiling may improve melanoma risk stratification, surveillance, and individualized care.

A 2026 study links Agent Orange exposure to higher odds of acral melanoma in US veterans, highlighting the importance of early detection.

Phase 2 BEACON findings published in JAMA Dermatology demonstrate rapid improvements in disease activity and skin-related quality of life with oral brepocitinib.